Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Kidney Disease
100%
Receptor Agonist
100%
Glucagon-like
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
1 Receptor
100%
Finerenone
100%
Placebo
44%
Type 2 Diabetes Mellitus (T2DM)
33%
Urinary Albumin-to-creatinine Ratio
33%
Systolic Blood Pressure
22%
Estimated Glomerular Filtration Rate
22%
Concomitant Medications
22%
Treatment Discontinuation
11%
Hospitalization
11%
Blood Pressure
11%
Hyperkalemia
11%
Combination Therapy
11%
Clinical Trials
11%
Treatment Recommendations
11%
Kidney
11%
Renin-angiotensin System Inhibitors
11%
Safety Profile
11%
Cardiovascular Effects
11%
Kidney Function
11%
Synergistic Effect
11%
Concomitant Use
11%
Individual-level Analysis
11%
Treatment-related Adverse Events
11%
Medicine and Dentistry
Glucagon-Like Peptide-1 Agonist
100%
Chronic Kidney Disease
100%
Finerenone
100%
Sodium-Glucose Cotransporter 2 Inhibitors
100%
Placebo
44%
Maturity Onset Diabetes of the Young
33%
Creatinine
33%
Albumin
33%
Systolic Blood Pressure
22%
Glomerular Filtration Rate
22%
Adverse Event
11%
Blood Pressure
11%
Arm
11%
Clinical Trial
11%
Combination Therapy
11%
Kidney Function
11%
Renin Angiotensin Aldosterone System
11%
Hyperkalemia
11%
Cardiovascular System
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Finerenone
100%
sodium glucose cotransporter-2 inhibitors
100%
Placebo
44%
Creatinine
33%
Albumin
33%
Maturity Onset Diabetes of the Young
33%
Adverse Event
11%
Renin
11%
Angiotensin
11%
Hyperkalemia
11%
Combination Therapy
11%
Clinical Trial
11%